Royalty Pharma (RPRX) Panoramica del titolo
Royalty Pharma plc opera come acquirente di royalties biofarmaceutiche e finanziatore dell'innovazione nel settore biofarmaceutico negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 2/6 |
Premi
Analisi del rischio
RPRX Community Fair Values
Create NarrativeSee what 52 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Royalty Pharma plc
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$56.23 |
| Massimo di 52 settimane | US$56.50 |
| Minimo di 52 settimane | US$34.08 |
| Beta | 0.42 |
| Variazione di 1 mese | 4.19% |
| Variazione a 3 mesi | 21.32% |
| Variazione di 1 anno | 56.76% |
| Variazione a 3 anni | 82.92% |
| Variazione a 5 anni | 33.12% |
| Variazione dall'IPO | 26.36% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 19
RPRX: Royalty Deals And Buybacks Will Support Long Term Stock Upside
Analysts have raised their price target for Royalty Pharma stock to $66.00 from $60.61, citing updated views on fair value, discount rate, expected revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Royalty Pharma points to a cluster of higher price targets and supportive commentary around valuation, execution, and growth prospects.
Aggiornamento della narrazione • Jun 03
RPRX: Royalty Deals And Buybacks Will Shape Balanced Future Returns
Analysts have lifted their average price target for Royalty Pharma to about $59, up from roughly $52, citing updated views on long term revenue potential, higher expected profitability, and a lower assumed future P/E multiple. These factors are reflected in recent target increases from firms like Morgan Stanley and UBS, as well as positive commentary around the $250m Zymeworks financing deal.Recent updates
Aggiornamento della narrazione • Jun 19
RPRX: Royalty Deals And Buybacks Will Support Long Term Stock Upside
Analysts have raised their price target for Royalty Pharma stock to $66.00 from $60.61, citing updated views on fair value, discount rate, expected revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Royalty Pharma points to a cluster of higher price targets and supportive commentary around valuation, execution, and growth prospects.Aggiornamento della narrazione • Jun 03
RPRX: Royalty Deals And Buybacks Will Shape Balanced Future Returns
Analysts have lifted their average price target for Royalty Pharma to about $59, up from roughly $52, citing updated views on long term revenue potential, higher expected profitability, and a lower assumed future P/E multiple. These factors are reflected in recent target increases from firms like Morgan Stanley and UBS, as well as positive commentary around the $250m Zymeworks financing deal.Seeking Alpha • May 16
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
Summary Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma’s positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers. Read the full article on Seeking Alpha
Aggiornamento della narrazione • May 02
RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook
Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.Aggiornamento della narrazione • Apr 17
RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside
Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.Aggiornamento della narrazione • Apr 03
RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook
Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.Aggiornamento della narrazione • Mar 19
RPRX: Royalty Deals And Buybacks Will Support Future Upside
Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.Aggiornamento della narrazione • Mar 05
RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential
Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.Aggiornamento della narrazione • Feb 19
RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside
Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.Articolo di analisi • Feb 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Aggiornamento della narrazione • Feb 05
RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns
Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Articolo di analisi • Jan 22
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Aggiornamento della narrazione • Jan 21
RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside
Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.Aggiornamento della narrazione • Jan 07
RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power
Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Aggiornamento della narrazione • Dec 15
RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price
Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.Aggiornamento della narrazione • Dec 01
RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion
Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.Aggiornamento della narrazione • Nov 17
RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade
Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.Aggiornamento della narrazione • Nov 02
RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside
Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.Aggiornamento della narrazione • Sep 04
Emerging Therapies And Licensing Will Expand Royalty Opportunities
Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.Articolo di analisi • Jul 06
Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Seeking Alpha • Feb 13
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Summary Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Royalty Pharma: Key Strategic Updates To Be Priced In
Summary Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. Read the full article on Seeking AlphaSeeking Alpha • Nov 09
Royalty Pharma: Massive Opportunity Ahead
Summary Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy. Read the full article on Seeking AlphaRendimenti per gli azionisti
| RPRX | US Pharmaceuticals | US Mercato | |
|---|---|---|---|
| 7D | 6.2% | 9.0% | -2.6% |
| 1Y | 56.8% | 48.8% | 20.0% |
Ritorno vs Industria: RPRX ha superato il US Pharmaceuticals che ha restituito 40.6 % nell'ultimo anno.
Rendimento vs Mercato: RPRX ha superato il mercato US che ha restituito 18.6 % nell'ultimo anno.
Volatilità dei prezzi
| RPRX volatility | |
|---|---|
| RPRX Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: RPRX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 3% ) di RPRX è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1996 | 100 | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc opera come acquirente di royalties biofarmaceutiche e finanziatore dell'innovazione nel settore biofarmaceutico negli Stati Uniti. Il suo portafoglio è costituito da royalties su circa 35 terapie commercializzate e 20 prodotti candidati in fase di sviluppo che riguardano varie aree terapeutiche, quali malattie rare, oncologia, neuroscienze, malattie infettive, ematologia e diabete. L'azienda ha una collaborazione per il finanziamento della ricerca e dello sviluppo per portare avanti lo sviluppo di JNJ-4804, un farmaco in fase di sperimentazione per le malattie autoimmuni.
Royalty Pharma plc Riepilogo dei fondamenti
| RPRX statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$31.49b |
| Utili (TTM) | US$826.29m |
| Ricavi(TTM) | US$2.44b |
30.2x
Rapporto P/E10.2x
Rapporto P/SRPRX è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| RPRX Conto economico (TTM) | |
|---|---|
| Ricavi | US$2.44b |
| Costo del fatturato | -US$366.18m |
| Profitto lordo | US$2.81b |
| Altre spese | US$1.98b |
| Utili | US$826.29m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 1.86 |
| Margine lordo | 115.00% |
| Margine di profitto netto | 33.86% |
| Rapporto debito/patrimonio netto | 90.1% |
Come si è comportato RPRX nel lungo periodo?
Vedi performance storica e confrontoDividendi
1.7%
Rendimento attuale del dividendo47%
Rapporto di remunerazioneAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/26 06:10 |
| Prezzo dell'azione a fine giornata | 2026/06/26 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Royalty Pharma plc è coperta da 14 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |
| Prem Chulaki | CrispIdea |